A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2
Latest Information Update: 13 Dec 2024
Price :
$35 *
At a glance
- Drugs ARO ATXN2 (Primary)
- Indications Spinocerebellar ataxias
- Focus Adverse reactions
- Sponsors Arrowhead Pharmaceuticals
- 06 Dec 2024 Planned initiation date changed from 1 Nov 2024 to 1 Jan 2025.
- 06 Dec 2024 Status changed from not yet recruiting to recruiting.
- 12 Nov 2024 New trial record